Acta Oncologica最新文献

{"title":"Detection of disease recurrence in real-world patients with completely resected stage III cutaneous melanoma.","authors":"Tiina Peuranheimo, Anni Hellman, Siru Mäkelä, Kalle Mattila, Micaela Hernberg","doi":"10.2340/1651-226X.2026.45609","DOIUrl":"10.2340/1651-226X.2026.45609","url":null,"abstract":"<p><strong>Background and purpose: </strong>Optimal postoperative follow-up for high-risk cutaneous melanomas (CM) is unclear. We aimed to evaluate disease recurrences in patients with stage III CM before modern adjuvant therapies. Patient/material and methods: Three hundred and fifty patients with a median follow-up of 8.9 years at Helsinki University Hospital Comprehensive Cancer Center after complete resection of stage IIIA-D CM between 2008 and 2017 were identified. Information on baseline characteristics, recurrence patterns and survival were collected from electronic medical records.</p><p><strong>Results: </strong>One hundred and ninety patients (54.3%) developed disease recurrence with 258 recurrence events documented. Local recurrence occurred in 14.5, 27.0, 32.3 and 44.4% and distant metastases in 21.7, 40.5, 52.4 and 83.3% of patients with stage IIIA, IIIB, IIID and IIID, respectively. Median recurrence-free survival was not reached and 7.4 years in stage IIIA and IIIB compared to 2.9 and 0.9 years in IIIC and IIID. Routine computed tomography (CT) imaging revealed 51% of all recurrences and 64% of distant meta-stases. 13.2% of distant recurrences involved skin and soft tissues, 31.4 lungs, 34.0 other visceral organs and 21.5% brain. First recurrences occurred mostly during the first 2 years of follow-up (59.5-100% in stage IIIB-D) except for stage IIIA (45.0%). Most of recurrences detected by patients (58.0%), physical exams or ultrasound (76.1%) and routine CT (61.2%) occurred during the first 2 years.</p><p><strong>Interpretation: </strong>High rate of recurrences and distant metastases supports routine physical exams and CT particularly during the first years of postoperative follow-up, especially in stage IIIB-D CM.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"535-542"},"PeriodicalIF":2.7,"publicationDate":"2026-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13248745/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148196874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic pathways for lung cancer patients in Denmark: General practice events, first referral and stage at diagnosis.","authors":"Dorte Ejg Jarbøl, Peter Haastrup, Sanne Rasmussen, Gitte Bruun Lauridsen, Kirubakaran Balasubramaniam, Linda Juel Ahrenfeldt, Jesper Lykkegaard, Lisa Maria Sele Sætre","doi":"10.2340/1651-226X.2026.45851","DOIUrl":"10.2340/1651-226X.2026.45851","url":null,"abstract":"<p><strong>Background and purpose: </strong>This study examined lung cancer patients' diagnostic pathways, focusing on first healthcare contact, general practice events, referral choice, and stage at diagnosis.</p><p><strong>Patients and methods: </strong>General practices in three Danish regions participated in a retrospective survey of medical records for patients diagnosed with lung cancer between March 2019 and February 2021. General practitioners completed a questionnaire on initial contact, symptom presentation, diagnostic events and first referral. Socioeconomic data and tumor stage were retrieved from national registers. Associations between symptom presentation and diagnostic events were analysed.</p><p><strong>Results: </strong>Among 1069 patients, 72% had initial contact in general practice, 22% at a hospital and 5% with out-of-hours care. Of patients starting in general practice (n = 766), 36% presented specific cancer symptoms, 48% non-specific symptoms, 9% both and 7% were asymptomatic. Diagnostic events included hesitation to seek care (10%), declining investigation or non-adherence (4%) and initial management for another disease (33%). Men were more likely to decline investigation or fail to follow-up (odds ratio [OR] 4.32; 95% confidence interval 1.75-10.65). Non-specific symptoms increased the odds of referral for another condition (OR 1.48) or another cancer type (OR 2.99). Most patients were first referred to imaging (48%), whereas 16% entered a cancer care pathway and 18% were acutely hospitalised. Advanced stage was common (80%) and more likely among acutely hospitalised patients (OR 2.68).</p><p><strong>Interpretation: </strong>Most lung cancer patients present first in general practice. Non-specific symptoms are frequent and pose challenges for timely diagnosis.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"525-534"},"PeriodicalIF":2.7,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13234914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148142154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncological outcome and immune-checkpoint-blockade-induced toxicities in patients with cervical cancer - a Norwegian real-world cohort.","authors":"Katharina Bischof, Keira Matallah Fredriksen, Margrethe Bjørnstad, Mari Bunkholt Elstrand, Brynhildur Eyjolfsdottir, Alda Birgisdottir, Elisabeth Lillo, Guro Aune, Kristina Lindemann","doi":"10.2340/1651-226X.2026.45737","DOIUrl":"10.2340/1651-226X.2026.45737","url":null,"abstract":"<p><strong>Background and purpose: </strong>The introduction of immune checkpoint inhibitors (ICIs) into the treatment of patients with metastatic or recurrent cervical cancer has been shown to significantly prolong survival. In this study, we examined the clinical outcomes and tolerability of treatment with ICIs in patients with metastatic or recurrent cervical cancer in a real-world setting in Norway. Patient/material and methods: This retrospective cohort study included patients treated with an ICI in combination with chemotherapy or as single agent at Oslo University Hospital between 2016 and 2024. The primary oncological endpoint was progression-free survival (PFS). Secondary endpoints include overall survival (OS) as well as tolerability.</p><p><strong>Results: </strong>We included 57 patients with a median age of 53 years and a median follow-up of 15.2 months. Thirty-five patients were treated with an ICI in combination with chemotherapy (cohort 1), and or an ICI alone (n = 22) (cohort 2). Forty-six patients (81%) were treated for recurrent disease. In cohort 1, the median PFS was 12.4 months (95% CI: 9.0-15.7), and the median OS was 27.5 months (95% CI: 18.0-37.1). In cohort 2, the median PFS was 3.7 months (95% CI: 2.4-5.0), and the median OS was 9.3 months (95% CI: 4.3-14.4). Nine patients (16%) discontinued treatment due to toxicity.</p><p><strong>Interpretation: </strong>Our real-world data on the use of ICIs alone or in combination showed antitumour efficacy comparable to that reported in clinical studies in patients with advanced or recurrent cervical cancer. Our discontinuation rate highlights that toxicity management and mitigation are paramount when novel drugs are introduced in clinical algorithms.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"518-524"},"PeriodicalIF":2.7,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13234913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148136331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective evaluation and clinical outcomes of adaptive radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC).","authors":"Ingvild Helø Carlsen, Vilde Ragnvaldsen Dyvik, Tuva Borgund Johannessen, Kristine Fjellanger, Inger Marie Sandvik, John-Vidar Hjørnevik, Turid Husevåg Sulen, Tone Nybø, Johanna Austrheim Hundvin, Sara Margareta Cecilia Pilskog, Øystein Fløtten, Vilde Drageset Haakensen, Liv Bolstad Hysing","doi":"10.2340/1651-226X.2026.45745","DOIUrl":"10.2340/1651-226X.2026.45745","url":null,"abstract":"<p><strong>Background and purpose: </strong>Locoregional tumor control is strongly associated with survival for non-small cell lung cancer, emphasizing the importance of precise radiotherapy delivery. This study aims to evaluate a traffic light adaptation protocol regarding target coverage, protocol performance and patient outcomes.</p><p><strong>Material and methods: </strong>From 2019 to 2022, we prospectively enrolled inoperable non-small cell lung cancer patients. We acquired daily cone-beam computed tomography and traffic light registrations, classifying anatomical changes and need of action. Using repeated computed tomography (rCT) in week 1 and 3 for dosimetric evaluation, we recalculated clinical target volume (CTV) D98% and V95% with and without adaptation, and compared traffic light registrations with the actual dose distribution. Protocol performance was evaluated by the sensitivity and specificity in detecting CTV V95% < 98%.</p><p><strong>Results: </strong>Among 45 patients with complete registrations, baseline shift and tumor shrinkage were most common changes, leading to corrections from bone to tumor match in 37.8% and replanning in 13.3% of patients. Among 38 patients with at least one rCT, 15.8% would have received insufficient CTV coverage without adaptation. Protocol sensitivity, specificity and balanced accuracy were 83.3, 88.6, and 85.7%, respectively. For 38 stage II-III patients, median overall survival was 43.5 months (95% confidence interval [CI]: 32.9-54.1), median time to locoregional failure 27.4 months (95% CI: 0-61.8) and median estimated time to distant failure 30.7 months (CI not estimated due to censoring).</p><p><strong>Interpretation: </strong>The protocol identified relevant changes, improving target coverage without increasing organ at risk doses. With appropriate training, protocol performance was good, and clinical outcomes were consistent with international results.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"476-484"},"PeriodicalIF":2.7,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13221713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148025608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of absolute dose calculation of a single 125I-seed for ophthalmic brachytherapy within distance range 1-15 mm using a diode detector.","authors":"Anna Rintala, Vappu Reijonen, Assi Valve, Mikko Tenhunen","doi":"10.2340/1651-226X.2026.45688","DOIUrl":"10.2340/1651-226X.2026.45688","url":null,"abstract":"<p><strong>Background and purpose: </strong>Intraocular tumors can be treated with brachytherapy. Dosimetry of ophthalmic applicators is challenging due to short distance ranges and steep dose gradients. Measurements are sensitive to the structure of the dosimeter, and correction methods specific to 125I-source are needed for validation measurements of dose distribution.</p><p><strong>Material and methods: </strong>We measured dose profiles of I25.S16 seed using diode detector in a water phantom at 2 and 5 mm above surface of acrylic (PMMA) and gold backing. Volume averaging effect was corrected by the ratio of dose calculated with AAPM TG-43 formalism at the center point and the dose average within the detector element area. The angular sensitivity was measured at a constant radius around the seed. The effect of gold backing was evaluated from measurements with and without gold slab behind the seed. Measurements were normalized to calculated value at the distance of 10 mm from the seed using the air-kerma rate measured with a calibrated well chamber.</p><p><strong>Results: </strong>1D/3D gamma comparison pass rates 97% with criteria 0.3 mm/3% and 60% with 0.5 mm/5% were reached for a seed attached to PMMA and gold, respectively, in the range ± 10 mm.</p><p><strong>Interpretation: </strong>TG-43 calculated single seed distributions in PMMA were equivalent to measurements corrected for angular sensitivity and detector area. Gold-to-water ratio corrected calculations were not similarly comparable, and simple one-dimensional correction method is not accurate enough laterally. Diode dosimetry with these correction methods can be used for quality assurance and validation of clinical dose calculation of ophthalmic applicators.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"511-517"},"PeriodicalIF":2.7,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13221966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148025585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term lifestyle effects of prehabilitation in colorectal cancer.","authors":"Lisa D Geomini, Barend J Spanninga, Margot Hm Heijmans, Gerrit D Slooter","doi":"10.2340/1651-226X.2026.45608","DOIUrl":"10.2340/1651-226X.2026.45608","url":null,"abstract":"<p><strong>Background and purpose: </strong>Prehabilitation-a multimodal intervention aimed at optimizing patients' physical, nutritional and psychological status prior to surgery-has been shown to improve postoperative outcomes. However, the long-term impact of such programs on lifestyle remains poorly understood. Aim is to evaluate long-term lifestyle changes following a 4-week prehabilitation program prior to elective colorectal cancer (CRC) surgery and to compare patient-reported outcomes over a 24-month postoperative period between prehabilitation and control groups. Patient/material and methods: This single-center cross-sectional study combined a prehabilitation specific questionnaire with longitudinal data from the Prospective Dutch Colorectal Cancer (PLCRC) cohort. Questionnaires were distributed to CRC patients who underwent prehabilitation between 2021 and 2023. Longitudinal data-including validated measures of physical activity and quality of life-were compared between prehabilitation and control groups at 6, 12, and 24 months post-surgery.</p><p><strong>Results: </strong>A total of 137 prehabilitation questionnaires were completed. Over half of the patients reported sustained lifestyle changes, including increased physical activity, healthier dietary habits and smoking cessation. However, longitudinal analyses of the PLCRC cohort (n=140) showed no significant differences in physical activity or quality of life between the prehabilitation and control groups.</p><p><strong>Interpretation: </strong>Patients reported perceived meaningful, sustained, long-term lifestyle improvements following prehabilitation. The positive patient perspective may help support the broader implementation of prehabilitation in CRC care and highlights its potential to facilitate long-term lifestyle changes. However, these improvements were not reflected in the PLCRC data, likely due to high variability and the limited sample size of the dataset.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"485-492"},"PeriodicalIF":2.7,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13221714/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148025623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Change in skeletal muscle mass during systemic cancer treatment: a systematic review and meta-analysis.","authors":"Lukas Svendsen, Sandra Jensen, Stine Hansen, Victor Sørensen, Christoffer Johansen, Charlotte Suetta, Helle Pappot, Casper Simonsen, Lars Hermann Tang, Susanne Oksbjerg Dalton, Gunn Ammitzbøll, Bolette Skjødt Rafn","doi":"10.2340/1651-226X.2026.45726","DOIUrl":"10.2340/1651-226X.2026.45726","url":null,"abstract":"<p><strong>Background and purpose: </strong>Loss of skeletal muscle mass (SMM) is common during systemic cancer treatment, but the magnitude and variability across cancer and treatment types remain uncertain. We aimed to describe changes in SMM during systemic cancer treatment supported by pooled quantitative estimates.</p><p><strong>Patients/material and methods: </strong>We systematically searched PubMed, Embase, and Web of Science until April 2025 for longitudinal studies reporting SMM during chemotherapy and/or immunotherapy (± targeted therapy) in patients with cancer (PROSPERO CRD42022308388). Standardized mean changes (SMC) were pooled in random-effects meta-analyses using the restricted maximum-likelihood estimator with Hartung-Knapp adjustment. Heterogeneity was assessed using I². Risk of bias was assessed with the NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies.</p><p><strong>Results: </strong>Seventy-eight studies (n = 10,502; 52% male; median age 64 years [interquartile range, IQR: 34-77]) were included. Meta-analysis across cancers showed an association between systemic cancer treatment and decline in SMM (59 studies; n = 6,373; SMC = -0.24, 95% confidence interval [CI]: -0.29 to -0.20; I² = 92%), corresponding to -5% over a median interval of 90 (IQR: 71-129) days among studies (62%) reporting assessment intervals. Declines were most pronounced during chemotherapy (± targeted therapy).</p><p><strong>Interpretation: </strong>Declines in SMM are frequently observed during systemic cancer treatment, particularly during chemotherapy (± targeted therapy), although effect sizes were generally small per Cohen's thresholds. However, substantial heterogeneity limits interpretation of a single pooled estimate. Prospective studies with standardized methods are needed to clarify trajectories, mechanisms and clinical implications of SMM loss.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"493-510"},"PeriodicalIF":2.7,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13221715/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148025620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose-de-escalated focal radiotherapy for primary cutaneous T-cell lymphoma: a lesion-based retrospective cohort study.","authors":"Philipp Linde, Kathrin Wagner, Johannes Rosenbrock, Michael Oertel, Simone Ferdinandus, Jiaqi Fan, Emmanouil Fokas, Christian Baues","doi":"10.2340/1651-226X.2026.45728","DOIUrl":"10.2340/1651-226X.2026.45728","url":null,"abstract":"<p><strong>Background and purpose: </strong>Radiotherapy (RT) is effective for cutaneous T-cell lymphoma (CTCL), but the optimal focal dose remains debated. We evaluated lesion response, local control, toxicity and patient satisfaction after 2 × 4 Gy compared with higher-dose regimens. Patient/material and methods: This single-centre retrospective study included CTCL patients treated with RT between 1990 and 2019 at a German university hospital. Lesions receiving 2 × 4 Gy (low-dose) were compared with lesions treated with higher doses (median 34 Gy). Endpoints were complete response (CR), overall response (OR), 1- and 5-year local control rate (LCR; Kaplan-Meier/log-rank), in-field relapse and toxicity (common terminology criteria for adverse events/ Radiation Therapy Oncology Group (RTOG)-European Organisation for Research and Treatment of Cancer). Patient satisfaction Freiburg Index of Patient Satisfaction (FIPS) was assessed in a subsample.</p><p><strong>Results: </strong>Thirty-two patients with 227 lesions were analysed (195 low-dose; 32 higher-dose). CR was achieved in 88.2% vs 90.6% and OR in 94.4% vs 100%, respectively (low- vs higher-dose). LCR was inferior after low-dose RT, with 1- and 5-year LCR estimates of 82 and 67% versus 100 and 96% after higher-dose RT (log-rank p = 0.013). In-field relapse occurred in 20.1% (37/184) vs 3.6% (1/28) of lesions with follow-up (Fisher p = 0.034). No toxicity > grade 2 was observed, and did not differ between groups (p = 0.695 and p = 0.657). In 11 FIPS questionnaires, satisfaction was high (mean score 1.27; median 1).</p><p><strong>Interpretation: </strong>Low-dose 2 × 4 Gy yields excellent initial response with minimal toxicity, but inferior local control compared with higher-dose focal RT. Findings support intent-based dosing: 2 × 4 Gy for symptom-driven treatment with re-irradiation as a pragmatic option, and higher-dose RT when durable local control is the primary objective.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"468-475"},"PeriodicalIF":2.7,"publicationDate":"2026-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13213537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148013118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment and progression of patients in Sweden with metastatic castration-sensitive prostate cancer.","authors":"Johan Styrke, Åsa Jellvert, Marie Hjälm Eriksson, Fredrik Sandin, Elin Axén, Sam Jabbar, Kamilla Juhl Norgaard","doi":"10.2340/1651-226X.2026.45110","DOIUrl":"10.2340/1651-226X.2026.45110","url":null,"abstract":"<p><strong>Background and purpose: </strong>The metastatic castration-sensitive prostate cancer (mCSPC) treatment landscape in Sweden has evolved in recent years. The purpose of this study is to provide contemporary registry data on outcomes and treatment patterns in a nationwide cohort of Swedish patients with de novo mCSPC. Patient/material and methods: This retrospective cohort study included patients in Sweden with a clinical diagnosis of de novo mCSPC registered between January 1, 2017 and December 31, 2023. The primary outcome was time from de novo mCSPC diagnosis to mCRPC or death (2017-2023). Secondary outcomes included overall survival (OS), comorbidities, co-medication use, and treatment sequencing. OS, time to progression or death, and treatment sequencing for the 2017-2020 and 2021-2023 time periods were also analyzed.</p><p><strong>Results: </strong>A total of 2421 patients with de novo mCSPC were included in the primary analysis (mean age: 72.8 years). The median time to progression or death was 22.7 months (95% CI: 21.2-24.1), and the median OS was 49.8 months (95% CI: 47.0-52.6). Median time to progression or death increased from 19.9 months (95% CI: 18.6-21.2) in 2017-2020 to 30.0 months (95% CI: 26.6-33.3) in 2021-2023, while the proportion of patients receiving initial doublet or triplet therapy rose from 42.5 to 68.8%. No differences in OS were observed between different time periods.</p><p><strong>Interpretation: </strong>In Sweden (2017-2023), increased time to progression or death was observed in patients with de novo mCSPC.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"449-459"},"PeriodicalIF":2.7,"publicationDate":"2026-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13200255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147980030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival and relapse of Danish patients with thymic epithelial tumors.","authors":"Tine Østergaard, Caroline Van Alstine Bjerke, Eric Santoni-Rugiu, Thomas Hartvig Lindkær Jensen, Katharina Anne Perell, René Horsleben Petersen, Peter Meidahl Petersen","doi":"10.2340/1651-226X.2026.45407","DOIUrl":"10.2340/1651-226X.2026.45407","url":null,"abstract":"<p><strong>Background and purpose: </strong>This study aims to evaluate survival, relapse, comorbidities, and prognostic factors in patients with thymic epithelial tumours (TETs) to improve risk stratification for TET-related mortality and relapse and support evidence-based follow-up and treatment strategies. Patient/material and methods: The cohort consists of consecutive Danish patients diagnosed with thymoma, thymic carcinoma (TC), or thymic neuroendocrine tumor (NET) between January 1st, 2015 and December 31st, 2020, with follow-up data available. Data were collected from online medical records including disease characteristics, survival outcomes, comorbidities, and relapse. Statistical analyses were performed in R 4.3.2 and the prognostic value baseline traits were analyzed using Cox Proportional Hazards models.</p><p><strong>Results: </strong>Our cohort comprised 282 patients with a mean diagnostic age of 65 years and the following histological distribution: thymoma (85%), TC (13.6%), and NET (1.4%). During the 72-month mean follow-up, 65 deaths occurred yielding overall survival (OS) of 81% in patients with thymoma and 47% in patients with TC. TET-related deaths predominated in TC, yielding a cancer-specific survival) of 53% compared with 96% in thymoma. Reduced OS was associated with increasing age (p < 0.001) and advanced Tumor, Node, Metastasis-stage (III p < 0.05; IV p < 0.001). Disease progression was verified in 13/201 (6%) of thymoma patients with R0 or R1 resection.</p><p><strong>Interpretation: </strong>We report a high OS of Danish TET patients compared to existing population-based studies. The occurrence of TET-related mortality and disease progression in patients with thymoma and TC, highlights the need for long-term follow-up and therefore risk stratification in TET management.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"460-467"},"PeriodicalIF":2.7,"publicationDate":"2026-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13200513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147980023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}